HeraMED (ASX:HMD)
Company Profile
Check out the latest news, insights and unique analysis brought to you by Stockhead's team of business journalists and industry experts on HeraMED.
RELATED STOCKHEAD STORIES
Health Check: Amplia shares surge on pancreatic cancer trial results; Immutep offers hope
Health Check: More, please! When record results are not good enough for expectant investors
HeraMED teams up with Metronomic for postpartum care in US
Institutional investors power HeraMED’s maternity care revolution with $1m
ASX health stocks developing tech to bridge labour gaps
ASX Quarterly Health Wrap: Lift-off for ED nasal spray and record users for pregnancy-monitoring platform
Health Check: Nothing to spook investors in CSL’s update as the blood still flows thick
ASX Small Caps Lunch Wrap: ASX up, and things are pretty quiet for a Wednesday
Rise and Shine: Everything you need to know before the ASX opens
HeraMED revolutionising maternity care with digital technology
User base expands for HeraMED’s remote pregnancy monitoring platform
Check Up: Aussie biotech Ternarx to pioneer next-gen cancer medicine, and recent ASX health winners
Rise and Shine: Everything you need to know before the ASX opens
